07:09 AM EDT, 05/02/2024 (MT Newswires) -- Regeneron Pharmaceuticals ( REGN ) reported Q1 non-GAAP net income Thursday of $9.55 per diluted share, down from $10.09 a year earlier.

Analysts polled by Capital IQ expected $10.10.

Revenue for the quarter ended March 31 was $3.15 billion, compared with $3.16 billion a year earlier.

Analysts polled by Capital IQ expected $3.22 billion.

The company said its board recently authorized a new $3 billion share repurchase program.

Price: 880.00, Change: -23.48, Percent Change: -2.60